Multimodal Therapy Impact on Pancreatic Cancer Survival
NCT ID: NCT06938906
Last Updated: 2025-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
405 participants
OBSERVATIONAL
2011-01-03
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis: Change of treatment strategies involving increased utility of neoadjuvant chemotherapy and aggressive surgical approaches of extended pancreatectomy improved the overall and progression free survival in the patients with pancreatic cancer.
Participants received curative treatment for pancreatic cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
NCT05888129
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
NCT05268692
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
NCT06873178
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
NCT06208436
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
NCT05634564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
The patient of pancreatic cancer, who began to have treatment in the period between 2011 to 2017.
No interventions assigned to this group
Group B
The patient of pancreatic cancer, who began to have treatment in the period between 2018 to 2022.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received curative surgery
Exclusion Criteria
* Cases with palliative or R2 resection were also excluded from the analysis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cheng Kung University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ting-Kai Liao
Principal Investigator, Director of Specialized Ward for Division of General Surgery, Department of Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan-Shen Shan, MD., PhD.
Role: STUDY_CHAIR
Department of Surgery, National Cheng Kung University Hospital
Ting-Kai Liao, MD.
Role: STUDY_DIRECTOR
National Cheng-Kung University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cheng Kung University Hospital
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCKUH-11405009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.